Drug Approval | November 14, 2022
Stelis receives recommendation from EMA granting market authorization for Kauliv
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The company increases its efficiency and is able to face the growing demand for its services.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
100% efficacy against severe Covid-19 disease and hospitalizations
Subscribe To Our Newsletter & Stay Updated
